Abu Dhabi's MGX has joined a USD 2.1 billion Series B funding round for Isomorphic Labs, a UK-based AI-driven drug design company. The round drew participation from existing backers Alphabet and Google Ventures alongside new investors Temasek, CapitalG, and the UK Sovereign AI Fund.
Isomorphic Labs develops proprietary AI models and datasets to identify viable drug candidates and accelerate the creation of new medicines. The fresh capital will fund global expansion, new hires, and the continued development and deployment of its AI drug design platform.
The investment marks another strategic move by MGX, Abu Dhabi's tech-focused state-backed investment vehicle, into frontier AI applications – extending the emirate's growing footprint across the global AI value chain beyond infrastructure and into life sciences.
Gulf Economist Staff Writer